share_log

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K:重大事件
美股SEC公告 ·  06/06 03:02
牛牛AI助理已提取核心訊息
On June 5, 2024, Novo Integrated Sciences, Inc. announced that its subsidiary, Acenzia Inc., has been chosen by Protein Industries Canada to participate in a project aimed at introducing new protein products with enhanced nutritional profiles to the global market. The project, with a total investment of approximately $5.4 million, will focus on the development, reformulation, and commercialization of three consumer-ready protein products. Acenzia will contribute around $600,000, while Protein Industries Canada and two other partner companies will invest $2.3 million and $2.5 million, respectively. The initiative will span three phases and aims to offer plant-based protein alternatives that are comparable to whey protein isolate in terms of quality, sensory experience, and muscle health benefits. The products are intended for various consumer segments, including...Show More
On June 5, 2024, Novo Integrated Sciences, Inc. announced that its subsidiary, Acenzia Inc., has been chosen by Protein Industries Canada to participate in a project aimed at introducing new protein products with enhanced nutritional profiles to the global market. The project, with a total investment of approximately $5.4 million, will focus on the development, reformulation, and commercialization of three consumer-ready protein products. Acenzia will contribute around $600,000, while Protein Industries Canada and two other partner companies will invest $2.3 million and $2.5 million, respectively. The initiative will span three phases and aims to offer plant-based protein alternatives that are comparable to whey protein isolate in terms of quality, sensory experience, and muscle health benefits. The products are intended for various consumer segments, including medical nutrition, active living, and high-performance sports. Acenzia's involvement leverages its expertise in contract manufacturing, product formulation, R&D, and sustainable packaging to create ecologically friendly, evidence-based plant protein products. Novo Integrated Sciences, Inc., the parent company, is known for its multidisciplinary healthcare ecosystem and product innovation, focusing on a holistic approach to health and wellness.
2024年6月5日,Novo Integrated Sciences, Inc.宣佈其子公司Acenzia Inc.被Protein Industries Canada選中參與一個旨在向全球市場推出增強營養價值的新蛋白質產品的項目中。該項目總投資額約為540萬美元,將重點發展、改良和商業化三種消費者即食蛋白質產品。Acenzia將提供約60萬美元,而Protein Industries Canada和另外兩家合作夥伴公司將分別投資230萬美元和250萬美元。該項目將分三個階段進行,旨在提供與乳清蛋白分離物相當的質量、感官體驗和肌肉健康益處的植物蛋白質替代品。這些產品旨在為包括醫療營養、積極生活...展開全部
2024年6月5日,Novo Integrated Sciences, Inc.宣佈其子公司Acenzia Inc.被Protein Industries Canada選中參與一個旨在向全球市場推出增強營養價值的新蛋白質產品的項目中。該項目總投資額約為540萬美元,將重點發展、改良和商業化三種消費者即食蛋白質產品。Acenzia將提供約60萬美元,而Protein Industries Canada和另外兩家合作夥伴公司將分別投資230萬美元和250萬美元。該項目將分三個階段進行,旨在提供與乳清蛋白分離物相當的質量、感官體驗和肌肉健康益處的植物蛋白質替代品。這些產品旨在為包括醫療營養、積極生活和高效運動在內的各種消費者群體提供。Acenzia的參與利用其在合同製造、產品配方、研發和可持續包裝方面的專業知識,創造生態友好、以證據為基礎的植物蛋白產品。母公司Novo Integrated Sciences, Inc.以其多學科醫療保健生態系統和產品創新聞名,專注於綜合健康和福祉的方法。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。